We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
Read MoreHide Full Article
Pfizer’s(PFE - Free Report) non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec as well as those acquired from Seagen (December 2023). The trend is expected to have continued in the fourth quarter.
In the past year, Pfizer’s stock has declined 0.2% compared with a decrease of 2.5% for the industry.
Image Source: Zacks Investment Research
Drug Sales Estimates: Vyndaqel, Prevnar & Eliquis
Vyndaqel/Vyndamax sales are likely to have benefited from continued demand growth, primarily in the United States and developed Europe.
Sales of Prevnar family of vaccines declined in the last two quarters due to fewer adult vaccinations in the United States and lower pediatric indication sales in certain emerging markets and international developed markets. We expect these factors to have continued to hurt sales in the fourth quarter.
The Zacks Consensus Estimate, as well as our model estimate, for sales of Vyndaqel/Vyndamax is $1.52 billion.
The Zacks Consensus Estimate for sales of the Prevnar family of vaccines is $1.56 billion. Our model estimates Prevnar family vaccine sales to be $1.53 billion.
In addition, alliance revenues and direct sales from Eliquis are likely to have provided top-line support, driven by continued share gains in the oral anticoagulant market. However, sales are likely to have been hurt by generic competition in some international markets due to the loss of patent exclusivity.
The Zacks Consensus Estimate for alliance revenues from Eliquis is $1.66 billion, while our model estimate is $1.61 billion.
Expectations From PFE’s New Drugs & Seagen Products
We expect Pfizer’s several newly launched drugs like the RSV vaccine Abrysvo, Velsipity pill for ulcerative colitis, pentavalent meningococcal vaccine Penbraya and new gene therapies for hemophilia, Hympavzi (marstacimab) and Beqvez/Durveqtix to have contributed to top-line growth.
While Abrysvo sales are expected to have been driven by international market expansion, its sales in the United States are expected to have been impacted by the revised recommendations for RSV vaccinations issued in June 2024 by the US Advisory Committee on Immunization Practices (ACIP).
The antibody-drug conjugates or ADCs, Adcetris, Padcev, Tukysa and Tivdak, added to Pfizer’s portfolio with the Seagen acquisition in December 2023, boosted Pfizer’s oncology sales in the first three quarters of 2024. Pfizer has been particularly witnessing strong demand for Padcev.
Among other acquired products, Nurtec sales are likely to have improved sequentially, driven by strong demand in the United States and launches in international markets. However, regarding another newly acquired drug, Oxbryta, in September, Pfizer announced that it is voluntarily withdrawing all lots of the sickle cell disease drug from all global markets where it is approved. Sales of Oxbryta are likely to have been minimal in the fourth quarter.
PFE's COVID Products' Expected Performance
Though sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined in the past few quarters it seems their sales have stabilized somewhat. Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX - Free Report) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid.
In the third quarter, direct sales and alliance revenues from BioNTech for Comirnaty rose, driven by the favorable timing of stocking in the United States due to earlier-than-expected approval of the updated shot, partially offset by lower demand in international markets. Paxlovid revenues were also significantly higher than the year-ago levels, driven by strong demand in the United States backed by a recent COVID wave. Also, a one-time contractual delivery to the U.S. Strategic National Stockpile led to sales growth. It remains to be seen if the positive trend continued in the fourth quarter.
Our estimate for direct sales and alliance revenues from Comirnaty is $3.13 billion, while that for Paxlovid is $540.6 million.
The Zacks Consensus Estimate for direct sales and alliance revenues from Comirnaty is $3.27 billion, while that for Paxlovid is $589.0 million.
Estimates for Alnylam’s 2025 earnings have improved from a loss of 13 cents to earnings of 41 cents per share over the past 60 days. In the past year, Alnylam’s stock has risen 58.9%.
Alnylam beat estimates in three of the last four quarters while matching the same once, delivering a four-quarter average earnings surprise of 65.67%.
Estimates for BioMarin’s 2025 earnings have improved from $3.94 per share to $4.02 per share over the past 60 days. In the past year, BioMarin’s stock has declined 27.8%.
BioMarin beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 28.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
Pfizer’s (PFE - Free Report) non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec as well as those acquired from Seagen (December 2023). The trend is expected to have continued in the fourth quarter.
In the past year, Pfizer’s stock has declined 0.2% compared with a decrease of 2.5% for the industry.
Image Source: Zacks Investment Research
Drug Sales Estimates: Vyndaqel, Prevnar & Eliquis
Vyndaqel/Vyndamax sales are likely to have benefited from continued demand growth, primarily in the United States and developed Europe.
Sales of Prevnar family of vaccines declined in the last two quarters due to fewer adult vaccinations in the United States and lower pediatric indication sales in certain emerging markets and international developed markets. We expect these factors to have continued to hurt sales in the fourth quarter.
The Zacks Consensus Estimate, as well as our model estimate, for sales of Vyndaqel/Vyndamax is $1.52 billion.
The Zacks Consensus Estimate for sales of the Prevnar family of vaccines is $1.56 billion. Our model estimates Prevnar family vaccine sales to be $1.53 billion.
In addition, alliance revenues and direct sales from Eliquis are likely to have provided top-line support, driven by continued share gains in the oral anticoagulant market. However, sales are likely to have been hurt by generic competition in some international markets due to the loss of patent exclusivity.
The Zacks Consensus Estimate for alliance revenues from Eliquis is $1.66 billion, while our model estimate is $1.61 billion.
Expectations From PFE’s New Drugs & Seagen Products
We expect Pfizer’s several newly launched drugs like the RSV vaccine Abrysvo, Velsipity pill for ulcerative colitis, pentavalent meningococcal vaccine Penbraya and new gene therapies for hemophilia, Hympavzi (marstacimab) and Beqvez/Durveqtix to have contributed to top-line growth.
While Abrysvo sales are expected to have been driven by international market expansion, its sales in the United States are expected to have been impacted by the revised recommendations for RSV vaccinations issued in June 2024 by the US Advisory Committee on Immunization Practices (ACIP).
The antibody-drug conjugates or ADCs, Adcetris, Padcev, Tukysa and Tivdak, added to Pfizer’s portfolio with the Seagen acquisition in December 2023, boosted Pfizer’s oncology sales in the first three quarters of 2024. Pfizer has been particularly witnessing strong demand for Padcev.
Among other acquired products, Nurtec sales are likely to have improved sequentially, driven by strong demand in the United States and launches in international markets. However, regarding another newly acquired drug, Oxbryta, in September, Pfizer announced that it is voluntarily withdrawing all lots of the sickle cell disease drug from all global markets where it is approved. Sales of Oxbryta are likely to have been minimal in the fourth quarter.
PFE's COVID Products' Expected Performance
Though sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined in the past few quarters it seems their sales have stabilized somewhat. Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX - Free Report) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid.
In the third quarter, direct sales and alliance revenues from BioNTech for Comirnaty rose, driven by the favorable timing of stocking in the United States due to earlier-than-expected approval of the updated shot, partially offset by lower demand in international markets. Paxlovid revenues were also significantly higher than the year-ago levels, driven by strong demand in the United States backed by a recent COVID wave. Also, a one-time contractual delivery to the U.S. Strategic National Stockpile led to sales growth. It remains to be seen if the positive trend continued in the fourth quarter.
Our estimate for direct sales and alliance revenues from Comirnaty is $3.13 billion, while that for Paxlovid is $540.6 million.
The Zacks Consensus Estimate for direct sales and alliance revenues from Comirnaty is $3.27 billion, while that for Paxlovid is $589.0 million.
PFE’s Zacks Rank & Stocks to Consider
Pfizer has a Zacks Rank #3 (Hold) currently. A couple of better-ranked stocks are Alnylam Pharmaceuticals (ALNY - Free Report) and BioMarin (BMRN - Free Report) , both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer Inc. Price and Consensus
Pfizer Inc. price-consensus-chart | Pfizer Inc. Quote
Estimates for Alnylam’s 2025 earnings have improved from a loss of 13 cents to earnings of 41 cents per share over the past 60 days. In the past year, Alnylam’s stock has risen 58.9%.
Alnylam beat estimates in three of the last four quarters while matching the same once, delivering a four-quarter average earnings surprise of 65.67%.
Estimates for BioMarin’s 2025 earnings have improved from $3.94 per share to $4.02 per share over the past 60 days. In the past year, BioMarin’s stock has declined 27.8%.
BioMarin beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 28.70%.